An Exploration of the Relationship Between Serum Cytokine Levels and the Clinical Efficacy of Vedolizumab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06855862

Enrollment

105

Registered

2025-03-04

Start date

2020-11-05

Completion date

2024-02-02

Last updated

2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis (UC)

Brief summary

It is uncertain the relationship between serum cytokine levels and the clinical efficacy of vedolizumab in the treatment of ulcerative colitis. The effects of cytokines on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed. Methods: Patients with UC were recorded. These patients were detected the levels of cytokines.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* UC patients Treated with Vedolizumab

Exclusion criteria

* pregnant * had cognitive/developmental disorders that affected their ability to complete the study procedures * had medical illness or therapies potentially affecting bone, nutrition or growth status

Design outcomes

Primary

Measure	Time frame
The partial Mayo score was applied to evaluate the clinical activity UC patients	16 week and 34 week

Countries

China

Outcome results